StockMarketWire.com - Biotherapeutics company PureTech Health said founded entity Vedanta Biosciences had appointed Jeffrey Silber as its chief medical officer.
Silber had previously worked at Merck, AbbVie and EMD Serono, and will guide the advancement of the company's clinical programmes.
Vedanta Biosciences, which develops bacteria-based treatments for a range of conditions, had also secured $15m from Oxford Finance to further support its pipeline development.
This included four clinical-stage product candidates currently being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel disease, food allergy and advanced and metastatic cancers.
At 1:09pm: [LON:PRTC] Puretech Health PLC share price was +13.25p at 283.25p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.